



10th Anniversary of *Biomedicines*—Intestinal Homeostasis and the Crosstalk within the Gut-Liver Axis

Guest Editors:

Dr. Jose Laparra Llopis

Madrid Institute for Advanced
Studies in Food (IMDEA Food),
Madrid, Spain

**Dr. Juan Antonio Giménez-
Bastida**

Laboratory of Food and Helath,
Research Group on Quality,
Safety and Bioactivity of Plant
Foods, Department Food Science
and Technology, CEBAS-CSIC,
P.O. Box 164, Campus de
Espinardo, 30100 Murcia, Spain

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

Dear Colleagues,

The study of immune signals that stem at the intestinal level is an emerging field in immunology contributing to a better understanding of innate immune biology and the underlying events triggering immunometabolic effects within the gut-liver axis. In the context of biomedicine, intestinal homeostasis and the crosstalk within the gut-liver axis represent a path forward to selectively develop and maintain a long-lasting immune response(s). Intestinal immune interventions have been shown to be effective in hepatic metabolism regulation and immunity targeting tissue resident innate lymphoid cells and peripheral monocytes. Thus, harnessing intestinal immunometabolic homeostasis may benefit liver health and the control of related diseases. However, fundamental questions remain about immune and metabolic events that overall require a concerted effort to overcome the usually fragmented and compartmentalized approach to address the gut-liver axis. Identification and development of those, and the definition of their biomedical translation based on life sciences, can greatly accelerate our progress toward precision medicine in health promotion.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)